NIKKEI 225
39,215.32 -451.75 (-1.14%) HANG SENG
17,783.04 -306.89 (-1.70%) CRUDE OIL
80.55 -0.35 (-0.43%) GOLD FUTURES
2,309.50 -3.70 (-0.16%) DOW
39,127.80 +15.64 (+0.04%) Bitcoin GBP
48,284.19 -1,065.98 (-2.16%)
ZNTL Oct 2024 17.500 call
| Previous close | 1.4000 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 17.50 |
| Expiry date | 2024-10-18 |
| Day's range | 1.4000 - 1.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
- Zacks
Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold
Zentalis' (ZNTL) three studies evaluating azenosertib for three different cancer indications face the FDA's partial clinical hold following the death of two patients.
GlobeNewswireZentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
FDA has placed a partial clinical hold on ZN-c3-001, DENALI and TETON monotherapy studies of azenosertib Monotherapy data to be presented in the second half of 2024 Conference call to be held today, June 18, 8:00 am ET SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today anno
